Premium
Effects of phase I periodontal treatment on gingival crevicular fluid levels of matrix metalloproteinase‐3 and tissue inhibitor of metalloproteinase‐1
Author(s) -
Tüter Gülay,
Kurtiş Bülent,
Serdar Muhittin,
Yücel Ayşegül,
Ayhan Eylem,
Karaduman Burcu,
Özcan Gönen
Publication year - 2005
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/j.1600-051x.2005.00816.x
Subject(s) - medicine , matrix metalloproteinase , matrix metalloproteinase 9 , chronic periodontitis , clinical attachment loss , tissue inhibitor of metalloproteinase , periodontitis , dentistry , gastroenterology , clinical significance
Objectives: The aim of this study was to evaluate the effects of phase I periodontal treatment on gingival crevicular fluid (GCF) levels of matrix metalloproteinase (MMP)‐3 and tissue inhibitors of metalloproteinase (TIMP)‐1. Methods: Plaque index, gingival index, pocket depth and clinical attachment loss were recorded and GCF samples were collected from 20 chronic periodontitis (CP) patients and 20 periodontally healthy controls (C) before treatment. CP patients received phase I periodontal treatment and all clinical parameters were recorded and GCF samples were collected once more after treatment. Assays were performed by an enzyme‐linked immunosorbent assay. Results: All of the clinical parameters improved significantly after the therapy ( p <0.05). Baseline GCF levels of MMP‐3 were significantly higher than C and that level was reduced significantly by treatment compared with baseline levels ( p <0.05). Baseline GCF levels of TIMP‐1 were lower than post‐treatment levels and C ( p <0.05). GCF levels of TIMP‐1 increased significantly by treatment compared with baseline levels ( p <0.05). Conclusion: This study shows that the clinical improvements after phase I periodontal therapy are accompanied by reduction in MMP‐3 and increasing in TIMP‐1 GCF levels.